BCLI Brainstorm Cell Therapeutics Inc

Price (delayed)

$3.39

Market cap

$123.12M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.95

Enterprise value

$93.66M

Highlights
BCLI's quick ratio has soared by 172% YoY and by 31% QoQ
The EPS has increased by 17% year-on-year and by 11% since the previous quarter
The net income has decreased by 15% YoY but it has increased by 4.6% QoQ

Key stats

What are the main financial stats of BCLI
Market
Shares outstanding
36.32M
Market cap
$123.12M
Enterprise value
$93.66M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.35
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$30.04M
EBITDA
-$29.81M
Free cash flow
-$29.53M
Per share
EPS
-$0.95
Free cash flow per share
-$0.83
Book value per share
$1.01
Revenue per share
$0
TBVPS
$1.36
Balance sheet
Total assets
$48.57M
Total liabilities
$12.37M
Debt
$6.48M
Equity
$36.2M
Working capital
$32.84M
Liquidity
Debt to equity
0.18
Current ratio
5.01
Quick ratio
4.92
Net debt/EBITDA
0.99
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-80%
Return on equity
-113%
Return on invested capital
-514.7%
Return on capital employed
-74.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCLI stock price

How has the Brainstorm Cell Therapeutics stock price performed over time
Intraday
-2.59%
1 week
1.5%
1 month
-11.26%
1 year
-78.58%
YTD
-25.17%
QTD
-10.79%

Financial performance

How have Brainstorm Cell Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$30.31M
Net income
-$30.36M
Gross margin
N/A
Net margin
N/A
Brainstorm Cell Therapeutics's operating income has decreased by 15% YoY but it has increased by 4.4% QoQ
The net income has decreased by 15% YoY but it has increased by 4.6% QoQ

Growth

What is Brainstorm Cell Therapeutics's growth rate over time

Valuation

What is Brainstorm Cell Therapeutics stock price valuation
P/E
N/A
P/B
3.35
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 17% year-on-year and by 11% since the previous quarter
BCLI's price to book (P/B) is 88% less than its 5-year quarterly average of 28.3 and 78% less than its last 4 quarters average of 15.5
The equity has grown by 2.1% from the previous quarter

Efficiency

How efficient is Brainstorm Cell Therapeutics business performance
The return on assets has surged by 69% year-on-year and by 24% since the previous quarter
BCLI's ROIC has soared by 52% QoQ
The company's return on equity rose by 29% QoQ

Dividends

What is BCLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCLI.

Financial health

How did Brainstorm Cell Therapeutics financials performed over time
Brainstorm Cell Therapeutics's current ratio has surged by 172% YoY and by 30% QoQ
BCLI's quick ratio has soared by 172% YoY and by 31% QoQ
BCLI's debt is 82% less than its equity
The company's debt to equity fell by 18% YoY and by 10% QoQ
BCLI's debt is down by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.